Dear Editor,

Despite the improvement in prophylaxis by vaccination, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated pathology, COVID-19, still constitute a challenge. Clinicians lack effective treatments and robust predictors to identify patients who will develop severe disease during their stay. The role of cytokines (e.g., IL-6) as biomarkers and therapeutic targets was evaluated at the beginning of the pandemic. However, their relevance are still being discussed.1 Patients with severe COVID-19 show an impairment of the immune system allowing secondary infections, 2–5 and numerous studies have found how T cell polyfunctionality decreases.5,6 In this regard, immune checkpoints (ICs), a family of molecules known for their ability to modulate immune response and induce T cell exhaustion and apoptosis, become interesting not only as potential early biomarkers of patients’ evolution but also as possible pharmaceutical targets.7

Thus, we recruited 69 patients and 15 healthy volunteers (HVs) from the emergency department (ED) of La Paz University Hospital. We analysed nine ICs on admission, previous to any treatment, in plasma from patients classified according to their outcome: mild (outpatients + hospitalized with no O2 requirement, n = 29), severe (hospitalized with O2 requirement, n = 26) and deceased (exitus, n = 14; 28-day mortality according WHO U07.1 code) (Figure 1A,B and Supplemental Figure S1 and Table S1). We found sCD25, sTim-3, Galectin-9, sPD-L1 and sCD86 exhibited differences between groups (Figure 1C–L). sCD25, sTim-3 and Galectin-9 showed to be increased in patients versus HVs in the mild group (Figure 1C–E). In addition, sCD25, sTim-3, Galectin-9, sPD-L1 and sPD-1 showed increased levels in severe patients and/or exitus compared with mild ones (Figure 1C–G). In contrast, the co-stimulatory molecule CD86 (sCD86) exhibited lower levels in mild and exitus patients compared with severe ones (Figure 1H). Levels of other ICs (sLAG-3, sCTLA-4 and sCD137) are shown in Figure 1I–L.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics

Next, we focused on the five ICs with significant differences between groups. sCD25, sTim-3, Galectin-9, and sPD-L1 showed a positive correlation with severity (Supplemental Figure S5). sCD86 did not show a patent trend (Supplemental Figure S5G). Severity in COVID-19 patients has been associated with differences in sex, age and comorbidities.8–10 Nonetheless, we did not find significant differences in IC levels between genders (Supplemental Figure S6) and only slight differences within comorbidities (Supplemental Figure S7). However, levels of both sCD25 and sTim-3 on admission not only correlated with a poor prognosis but also with age (Supplemental Figure S8). Other correlations are shown in Supplemental Figure S9.

We moved to study the changes in ICs throughout the hospital stay until discharge or exitus. Despite initial similarities between severe and exitus groups, their evolutions were disparate (Figure 2). Levels of sCD25, sTim-3 and Galectin-9 for mild and severe patients showed a trend toward the levels reported for HVs, while exitus exhibited a progressive elevation (Figure 2, right panels). Levels of sCD86 increased or levelled off in patients in the mild and severe groups, in contrast to the decrease observed in exitus (Figure 2E). Similar results were obtained when the analysis was performed using days from onset of symptoms (Supplemental Figure S10).

To explore the possible role of ICs in both the T cell exhaustion and lymphocytopenia reported in patients with COVID-19,4,5 we calculated the correlation between absolute lymphocyte count (ALC) and levels of circulating ICs on admission. Levels of sCD25, sTim-3, Galectin-9 and sPD-L1, but not sCD86, showed a negative correlation with
A. Patients were assessed for eligibility. 29 were excluded:
5 were enrolled in a clinical trial 8 declined to participate
10 were negative for SARS-CoV-2 infection 6 received some medication before being enrolled.

B. Patients were divided according to their health care requirements and evolution.

Mid (n=29)  Severe (n=26)  Exitus (n=14)

C. sCD25

D. sTim-3

E. Galactin-9

F. sPD-L1

G. sPD-1

H. sCD86

I. sLAG-3

J. sCTLA-4

K. sCD137

L. Heatmap showing Z-Score distribution.
Moreover, negative correlation between T cell proliferation and circulating levels of sCD25, sTim-3 and Galectin-9 was also observed (Supplemental Figure S11B-C). Along these lines, a significant increase in the response and a reduction of apoptosis of CD4+ and CD8+ T cells from COVID-19 patients was experienced when anti-Tim-3 and anti-Galectin-9 blocking antibodies were used ex vivo (Figure S11D-G).

We moved to analyse whether ICs are stronger severity biomarkers than cytokines in COVID-19. We analysed the levels of 12 cytokines/chemokines in our cohort. Only CCL-2, CXCL10, IL-6 and IL-8 showed significant differences between groups (Supplemental Figure S13). Next, using an area under the ROC curve (Area Under the Curve/Receiver Operating Characteristic [AUC/ROC]) analysis, we compared ability as predictor of the ICs, chemokines and cytokines. We found sCD25 and sTim-3 exhibited the highest AUCs for both mortality and ICU requirement prediction (Supplemental Figures S14 and S15) of all the molecules studied.

Beyond ICs and cytokines, we studied the predictive potential of 53 variables including epidemiological, physiological and other relevant parameters by AUC/ROC and univariate regression (Table 1). We performed a binary logistic regression model, including the 14 variables with an AUC/ROC > 0.7 and statistical significance in univariate analysis. After 12 steps (Supplemental Table S2), the final model included age, SpO2/FiO2, D-Dimer, sCD25 and sCD86 as predictors of mortality (Figure 3A). The score obtained from this model showed an AUC/ROC of 0.9753 for mortality prediction (Figure 3B). The optimal cut-off calculated by the Youden index showed a sensitivity of 0.93 and a specificity of 1 (Figure 3C). Note this predictive capacity is remarkably higher compared to the performance of all 53 variables alone (none of them had an AUC/ROC > 0.84; Table 1).

To corroborate the relevance of this score, we estimated it in a prospective validation independent cohort of COVID-19 patients (n = 166, Supplemental Table S3). We classified those patients into two groups according to the cut-off estimated in the discovery cohort (Figure 3D). The chi-squared test showed statistically significant differences in mortality frequency between the groups (χ2 = 102.8; z = 10.14; Figure 3D), and the score performed the discrimination of survivors and exitus with a specificity of 0.93 and a sensitivity of 0.96 (Figure 3E).

In summary, our data demonstrated IC levels on admission are better mortality predictors than other biomarkers such as cytokines in COVID-19. Combination of ICs and other easily measurable parameters identifies at ED admission those patients with the worst outcome. In addition, our ex vivo assays suggested the potential of ICs as pharmaceutical targets.

ACKNOWLEDGEMENTS
This study was supported by Fundación Familia Alonso, Santander Bank, Reale Seguros, Fundación Mutua Madrileña, Fundación Uria, Fundación Caixa and Ayuntamiento de Madrid. In memoriam of Norma López-Collazo.

CONFLICT OF INTEREST
The authors have declared that no conflict of interest exists.

José Avendaño-Ortiz1,2
Roberto Lozano-Rodríguez1,2
Alejandro Martín-Quirós3
Verónica Terrón1,2
Charbel Maroun-Eid2
Karla Montalbán-Hernández1,2
Jaime Valentin-Quiroga1,2
Miguel Angel Garcia-Garrido3
Elena Muñoz del Val1,3
Álvaro del Balzo-Castillo1,3
Maria Peinado3
Laura Gómez1,2
Carmen Herrero-Benito3
Carolina Rubio1,2
José Carlos Casalvilla-Dueñas1,2
Paloma Gómez-Campelo1,4
Alejandro Pascual-Iglesias1,2
Carlos del Fresno1,2
Luis A. Aguirre1,2
Eduardo López-Collazo1,2,5

1 The Innate Immune Response Group, IdiPAZ, La Paz, University Hospital, Madrid, Spain
FIGURE 2  Longitudinal analysis of plasma immune checkpoint levels of patients with COVID-19 according to their evolution and hospital needs from admission. Longitudinal concentrations of plasma sCD25 (A), sTim-3 (B), Galectin-9 (C), sPD-L1 (D) and sCD86 (E) in patients with COVID-19 according to the severity group from admission are shown (left panels). Total area under the curves (AUCs) from 0 to 14 days after admission of longitudinal concentrations of plasma sCD25 (A), sTim-3 (B), Galectin-9 (C), sPD-L1 (D), and sCD86 (E) of patients with COVID-19 according to the severity group on admission are shown (central panels). Linear regression and curve slopes are shown in right panels. Dashed lines show the HV ranges of plasma immune checkpoint levels. Data are pg/mL concentrations, and subgroup differences were analysed by the one-way analysis of variance. Data represent mean ± SEM. ***p < 0.001; ****p < 0.0001; F, F-statistic
FIGURE 3  Score from the logistic mathematical model predicted the mortality of patients with COVID-19 in a validation cohort. (A) Wald backward stepwise regression, including, as variables, age, previous diagnosis of hypertension, respiratory rate, pulse oximetric saturation/fraction of inspired O2 ratio (SpO2/FiO2), lactate, ALC, ratio neutrophil/lymphocyte, platelets, D-Dimer, qSOFA, sCD25, sCD86 and sTim-3. The final model after 12 steps is shown. Units: age in years; SpO2/FiO2 in arbitrary units, D-Dimer in ng/mL, sCD25 and sCD86 in pg/mL. (B) ROC curve analysis for mortality prediction in discovery cohort (n = 69) of the score obtained from the logistic regression model including age, D-Dimer, sCD86, sCD25 and SpO2/FiO2 as variables. The optimal Youden point is shown. (C) Estimated score of discovery COVID-19 patients’ cohort according to their outcome. The dashed line indicates the optimal Youden cut-off for mortality prediction. Sensitivity and specificity of this cut-off is shown. (D) Patients from validation cohort (n = 166) were classified according to their outcome and the regression model score (low and high subgroups by using the optimal Youden cut-off). Patient number distribution and chi-square test statistics are shown. (E) Estimated score of validation COVID-19 patients’ cohort according to their outcome. The dashed line indicates the optimal Youden cut-off for mortality prediction. Data represented in box-and-whisker plots (min to max). Odds ratio (OR), sensitivity and specificity of this cut-off are shown. B, B weight coefficient; OR, odds ratio; OR CI 95, 95% confidence interval of odds ratio; SD, standard deviation of B; Wald, Wald statistic $X^2$, chi-square; z, z-statistic.

| Variable      | B   | SD  | Wald | OR  | OR CI 95 Low | OR CI 95 High |
|---------------|-----|-----|------|-----|--------------|---------------|
| Age           | 0.18381 | 0.075 | 6.03 | 1.202 | 1.0377       | 1.4404        |
| SpO2/FiO2     | -0.3345 | 0.016 | 4.50 | 0.967 | 0.9377       | 4.42419       |
| D-Dimer       | 0.00034 | 0.0002 | 4.34 | 1.0003 | 1.00002     | 1.0027        |
| sCD25         | 0.00113 | 0.0006 | 3.08 | 1.0011 | 0.99999     | 1.0024        |
| sCD86         | -0.01682 | 0.0096 | 3.07 | 0.9833 | 0.9650      | 1.0002        |

AUC = 0.9753 (0.927 to 1.000)

Sensitivity = 0.93 (0.66-0.998)
Specificity = 1 (0.935-1.00)

Mild (n=29)  Severe (n=26)  Exitus (n=14)
| Variable       | ROC AUC | \( p \)-value | OR          | Univariate logistic regression OR IC 95 | \( p \)-value |
|----------------|---------|--------------|-------------|----------------------------------------|--------------|
| Age\textsuperscript{*} | 0.8019  | .0005        | 1.0793      | 1.029183–1.131854                      | .0017        |
| Sex (male)     | 0.6130  | .1942        | 2.526       | 0.764313–8.35033                       | .1287        |
| AHT\textsuperscript{*} | 0.7026  | .0199        | 5.8800      | 1.533836–20.359662                     | .0091        |
| DM             | 0.5786  | .3667        | 2.2222      | 0.619494–7.971464                      | .2205        |
| CVD            | 0.5604  | .4878        | 1.7949      | 0.51024–6.313824                       | .3621        |
| CKD            | 0.5974  | .2631        | 4.0000      | 0.910787–17.567221                     | .0663        |
| OBESEITY       | 0.5552  | .5260        | 0.3462      | 0.040472–2.960613                      | .3327        |
| COPD           | 0.5883  | .3103        | 3.2667      | 0.776781–13.73761                      | .1062        |
| Onco           | 0.5006  | .9940        | 0.9808      | 0.100886–9.534592                      | .9866        |
| ImmunoD        | 0.5013  | .9881        | 0.9792      | 0.183563–5.22311                       | .9803        |
| Temperature    | 0.5812  | .3510        | 1.1719      | 0.627006–2.190483                      | .6191        |
| Heart rate     | 0.5396  | .6490        | 1.0084      | 0.976758–1.041001                      | .6081        |
| Resp rate\textsuperscript{*} | 0.7695  | .0200        | 1.1780      | 1.048269–1.323747                      | .0059        |
| SpO\textsubscript{2}\textsuperscript{*} | 0.7318  | .0077        | 0.8853      | 0.797259–0.982972                      | .0225        |
| FiO\textsubscript{2} | 0.6506  | .0835        | 1.2276      | 1.036604–1.453895                      | .0175        |
| SpO\textsubscript{2}/FiO\textsubscript{2}\textsuperscript{*} | 0.8214  | .0002        | 0.9802      | 0.968543–0.99202                       | .0011        |
| Lactate\textsuperscript{*} | 0.8364  | .0001        | 9.2471      | 2.633093–32.474967                     | .0005        |
| Absolute leukocytes | 0.5513  | .5556        | 1.0000      | 0.999919–1.000092                      | .8960        |
| ANC            | 0.5987  | .2568        | 1.0002      | 0.999983–1.000375                      | .0733        |
| ALC\textsuperscript{*} | 0.8234  | .0002        | 0.9999      | 0.994924–0.99884                       | .0018        |
| AMC            | 0.6110  | .2020        | 0.9999      | 0.99464–1.001913                       | .3514        |
| N/L ratio\textsuperscript{*} | 0.7974  | .0006        | 1.0658      | 1.005046–1.13017                       | .0333        |
| Platelets\textsuperscript{*} | 0.7383  | .0062        | 0.9999      | 0.999985–0.999998                      | .0095        |
| Ferritin       | 0.7403  | .0058        | 1.0005      | 0.999808–1.001173                      | .1588        |
| D-Dimer\textsuperscript{*} | 0.7435  | .0051        | 1.0004      | 1.000033–1.000805                      | .0332        |
| Creatinine     | 0.7221  | .0107        | 1.1703      | 0.793126–1.726702                      | .4283        |
| AST            | 0.5117  | .8932        | 1.0037      | 0.997514–1.009897                      | .2423        |
| ALT            | 0.5416  | .6330        | 0.9924      | 0.974032–1.011074                      | .4218        |
| LDH            | 0.6558  | .0734        | 1.0037      | 0.999925–1.007448                      | .0548        |
| CRP            | 0.6981  | .0229        | 1.0044      | 0.998406–1.010426                      | .1506        |
| PCT            | 0.7110  | .0153        | 1.0199      | 0.984334–1.05684                       | .2761        |
| qSOFA\textsuperscript{*} | 0.8253  | .0002        | 9.3700      | 2.7216–32.259104                      | .0004        |
| sCD25\textsuperscript{*} | 0.7708  | .0019        | 1.0005      | 1.000001–1.001091                      | .0497        |
| sCD86\textsuperscript{*} | 0.7250  | .0096        | 0.9893      | 0.980009–0.998608                      | .0244        |
| sCD137         | 0.5266  | .7597        | 1.0011      | 0.988669–1.013693                      | .8628        |
| sCTLA-4        | 0.5818  | .3472        | 0.3824      | 0.828844–0.646805                      | 1.0468       |
| Galectin-9     | 0.6883  | .0305        | 1.0000      | 0.999988–1.000012                      | .1552        |
| sLAG-3         | 0.6052  | .2268        | 1.0001      | 0.999987–1.000254                      | .0759        |
| sPD-1          | 0.6110  | .2020        | 1.0211      | 0.99–1.052975                          | .1824        |
| sPD-L1         | 0.6920  | .0267        | 1.0129      | 0.999891–1.025989                      | .0503        |
| sTim-3\textsuperscript{*} | 0.7620  | .0025        | 1.0001      | 1.00001–1.000101                      | .0138        |
| CCL-2          | 0.6792  | .0395        | 1.0033      | 1.000145–1.006449                      | .0403        |
| CXCL10         | 0.6883  | .0305        | 1.0006      | 0.999967–1.001227                      | .0633        |
| IFNg           | 0.5571  | .5115        | 1.0010      | 0.998441–1.003467                      | .4582        |
| IL-1\textsuperscript{β} | 0.5227  | .7940        | 1.0389      | 0.872492–1.236977                      | .6685        |

(Continues)
| Variable      | ROC AUC | p-value | OR    | Univariate logistic regression OR IC 95 | p-value |
|---------------|---------|---------|-------|----------------------------------------|---------|
| IL-2          | 0.5922  | .2894   | 1.1051| 0.962296–1.269112                      | .1569   |
| IL-4          | 0.5961  | .2695   | 0.9703| 0.921224–1.022008                      | .2551   |
| IL-6          | 0.7169  | .0127   | 1.0022| 0.999664–1.004802                      | .0885   |
| IL-8          | 0.6409  | .1055   | 1.0307| 1.004042–1.05814                       | .0237   |
| IL-10         | 0.5338  | .6981   | 1.0058| 0.9953–1.016485                        | .2787   |
| IL-12p70      | 0.5597  | .4925   | 0.9428| 0.860632–1.022008                      | .2056   |
| IL-17A        | 0.5701  | .4204   | 0.9293| 0.801122–1.07795                       | .3327   |
| TNFα          | 0.567   | .442    | 1.0000| 0.913573–1.094726                      | .9903   |

The asterisk * labels those variables included in the Wald backward stepwise regression model. In bold are the areas under the ROC curve (AUC) > 0.5 and the p-values < .05.

Abbreviations: AHT, arterial hypertension; DM, history of diabetes mellitus; CVD, history of cardiovascular disease; CKD, history of chronic kidney disease; COPD, history of chronic obstructive pulmonary disease; Oncod, history of oncologic disease; Resp rate, respiratory rate; SpO2, oxygen saturation; FiO2, fraction of inspired oxygen; SpO2/FiO2, peripheral blood oxygen saturation to fraction of inspired oxygen ratio; ANC, absolute neutrophil counts; ALC, absolute lymphocyte counts; AMC, absolute monocyte counts; N/L Ratio, neutrophil to lymphocyte ratio; AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; CRP, c-reactive protein; PCT, procalcitonin; qSOFA, quick sequential organ failure assessment score.

2 Tumor Immunology Laboratory, IdiPAZ, La Paz University Hospital, Madrid, Spain
3 Emergency Department and Emergent Pathology Research Group, IdiPAZ La Paz University Hospital, Madrid, Spain
4 Biobank Platform, IdiPAZ, La Paz University Hospital, Madrid, Spain
5 CIBER of Respiratory Diseases (CIBERES), Madrid, Spain

Correspondence
Eduardo López-Collazo, IdiPAZ, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain.
Email: elopezc@salud.madrid.org
José Avendaño-Ortiz and Roberto Lozano-Rodríguez contributed equally.

ORCID
Roberto Lozano-Rodríguez https://orcid.org/0000-0003-0093-9707
Laura Gómez https://orcid.org/0000-0001-6460-0708
Luis A. Aguirre https://orcid.org/0000-0003-0903-9385
Eduardo López-Collazo https://orcid.org/0000-0003-1957-877X

REFERENCES
1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020;383:2333-2344. https://doi.org/10.1056/NEJMoa2028836
2. Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, et al. SARS-CoV-2 proteins induce endotoxin tolerance hallmarks: a demonstration in patients with COVID-19. J Immunol. 2021;207(1):162–174. https://doi.org/10.4049/jimmunol.2001449
3. Avendaño-Ortiz J, Lozano-Rodríguez R, Martín-Quirós A, et al. Proteins from SARS-CoV-2 reduce T cell proliferation: a mirror image of sepsis. Helixyon. 2020;6:e05635. https://doi.org/10.1016/j.helixyon.2020.e05635
4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2021;27;P992-1000.E3. https://doi.org/10.1016/j.chom.2020.04.009
5. Zheng H-Y, Zhang M, Yang C-X, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:541–543. https://doi.org/10.1038/s41423-020-0401-3
6. Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (Covid-19). Front Immunol. 2020;11:827. https://doi.org/10.3389/fimmu.2020.00827
7. Gambichler T, Reuther J, Scheel CH, et al. Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection. Cancers (Basel). 2020;12:E3383. https://doi.org/10.3390/cancers12113383
8. Takahashi T, Ellingson MK, Wong P, et al Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315-320. https://doi.org/10.1038/s41586-020-02700-3
9. Zheng M, Wang X, Guo H, et al. The cytokine profiles and immune response are increased in COVID-19 patients with type 2 diabetes mellitus. J Diabetes Res. 2021;2021:9526701. https://doi.org/10.1155/2021/9526701
10. Bajaj V, Gadi N, Spilman AP, et al. Aging, immunity, and COVID-19: How age influences the host immune response to coronavirus infections? Front Physiol. 2021;11:571416. https://doi.org/10.3389/fphys.2020.571416

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.